benzyl N-(tert-butoxycarbonyl)-N-methylglycinate | 87746-58-5

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: benzyl N-(tert-butoxycarbonyl)-N-methylglycinate
• 英文别名: benzyl [(tert-butoxycarbonyl)(methyl)amino]acetate；N-[(1,1-dimethylethoxy)carbonyl]-N-methylglycine phenylmethyl ester；benzyl 2-[methyl-[(2-methylpropan-2-yl)oxycarbonyl]amino]acetate
• CAS: 87746-58-5
• 化学式: C₁₅H₂₁NO₄
• mdl: MFCD24392673
• 分子量: 279.336
• InChiKey: KWBVWKFIEDRABO-UHFFFAOYSA-N

物化性质

• 沸点：
  367.5±21.0 °C(Predicted)
• 密度：
  1.108±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  20
• 可旋转键数：
  7
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.466
• 拓扑面积：
  55.8
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  benzyl N-(tert-butoxycarbonyl)-N-methylglycinate 在 sodium hydride 、 碳酸氢钠 作用下， 以 四氢呋喃 、 二氯甲烷 、 N,N-二甲基乙酰胺 、 mineral oil 为溶剂， 反应 16.5h， 生成 1-[N-(2-benzyloxy-2-oxoethyl)-N-methylcarbamoyl]-5-fluorouracil
  参考文献：
  名称：

  Design, synthesis and in vitro drug release investigation of new potential 5-FU prodrugs

  摘要：

  In order to identify new efficient prodrugs of 5-fluorouracil (5-FU) and to develop an original targeting approach using 2-fluoro-2-deoxyglucose (FDG) as a potential drug carrier, eight original 5-FU derivatives were synthesized: 5-FU was attached by the N1 position of the pyrimidinic ring to the C1 position of the FDG structure either by direct coupling (2a) or via various spacers (3, 6a-c, 10b and 19). A new sensitive high-performance liquid chromatography method was developed to simultaneously quantify 5-FU and its derivatives in human plasma and other relevant media at physiological temperatures. Half-lives were determined from the degradation profiles of these conjugates. Slow degradation of compounds 2a, 3, 10b and 19 was observed in vitro at 37 degrees C, but no 5-FU release was noticed. By contrast, the in vitro drug release profiles of compounds 6a-c followed pseudo-first-order kinetics, and 5-FU was found in all the media. The antiproliferative activity of the eight compounds was assessed in vitro by a fluorometric assay against two human solid cancer cell lines and one healthy cell line. A correlation was found between the activities of the compounds and their ability to release 5-FU efficiently. (C) 2011 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2011.04.010
• 作为产物：
  描述：

  叔丁氧羰酰基肌氨酸 以98%的产率得到benzyl N-(tert-butoxycarbonyl)-N-methylglycinate
  参考文献：
  名称：

  Hydroxyphenyl derivatives with HIV integrase inhibitory properties

  摘要：

  一种羟基苯基衍生物，选自以下化合物组： 当化合物I的结构中包含一个羧基时，其药用可接受盐；当化合物I的结构中包含一个氨基时，其药用可接受铵盐。其中，n为1、2或3，e为1、2或3，Hal代表卤素原子（如Cl、Br、F或I），p为0、1或2，r为0、1或2，X和X′各自独立代表单键，由1至4个碳原子组成的饱和直链或支链烃基，或由2至4个碳原子组成的直链或支链烃基，其中包含碳-碳双键，Ra代表H或—CH3，Raa代表H或—CH3；W可以代表氨基酸残基或片段。这些化合物可用于抑制HIV整合酶的活性。

  公开号：

  US06362165B1

文献信息

• [EN] COMPOUNDS AND COMPOSITIONS FOR OCULAR DELIVERY<br/>[FR] COMPOSÉS ET COMPOSITIONS POUR ADMINISTRATION OCULAIRE
  申请人：GRAYBUG VISION INC

  公开号：WO2020069353A1

  公开（公告）日：2020-04-02

  The present invention provides new prodrags of Sunitinib, Brinzolamide, and Dorzolamide and compositions to treat medical disorders, for example glaucoma, a disorder or abnormality related to an increase in intraocular pressure (TOP), a disorder requiring neuroprotection, age-related macular degeneration, or diabetic retinopathy.

  本发明提供了新的Sunitinib、Brinzolamide和Dorzolamide的前药，以及用于治疗医学疾病的组合物，例如青光眼、与眼内压增高有关的疾病或异常（TOP）、需要神经保护的疾病、年龄相关性黄斑变性或糖尿病视网膜病变。
• [EN] DRUGS TO TREAT OCULAR DISORDERS<br/>[FR] MÉDICAMENTS POUR TRAITER DES TROUBLES OCULAIRES
  申请人：GRAYBUG VISION INC

  公开号：WO2019210215A1

  公开（公告）日：2019-10-31

  The present invention provides new prodrugs of therapeutically active loop diuretics, including oligomeric prodrugs, and compositions to treat medical disorders, for example, ocular disorders such as glaucoma, a disorder or abnormality related to an increase in intraocular pressure (IOP), a disorder requiring neuroprotection, age-related macular degeneration, or diabetic retinopathy.

  本发明提供了治疗活性环利尿剂的新前药，包括寡聚前药，以及用于治疗医学疾病的组合物，例如眼部疾病，如青光眼，与眼内压增高相关的疾病或异常，需要神经保护的疾病，年龄相关性黄斑变性或糖尿病视网膜病变。
• [EN] METHODS FOR DELAYING, PREVENTING, AND TREATING ACQUIRED RESISTANCE TO RAS INHIBITORS<br/>[FR] MÉTHODES DE RETARDEMENT, DE PRÉVENTION ET DE TRAITEMENT DE LA RÉSISTANCE ACQUISE AUX INHIBITEURS DE RAS
  申请人：REVOLUTION MEDICINES INC

  公开号：WO2021257736A1

  公开（公告）日：2021-12-23

  The present disclosure relates to compositions and methods for the treatment of diseases or disorders (e.g., cancer) with bi-steric inhibitors of mTOR in combination with RAS inhibitors. Specifically, in some embodiments this disclosure includes compositions and methods for inducing apoptosis of tumor cells and/or for delaying, preventing, or treating acquired resistance to RAS inhibitors using bi-steric mTOR inhibitors.

  本公开涉及使用双-立体异构体mTOR抑制剂与RAS抑制剂联合治疗疾病或病状（例如，癌症）的配方和方法。具体而言，在某些实施方式中，本公开包括用于诱导肿瘤细胞凋亡和/或用于延迟、预防或治疗对RAS抑制剂获得性耐药性的双-立体异构体mTOR抑制剂的配方和方法。
• RAS INHIBITORS
  申请人：Revolution Medicines, Inc.

  公开号：US20210130326A1

  公开（公告）日：2021-05-06

  The disclosure features macrocyclic compounds, and pharmaceutical compositions and protein complexes thereof, capable of inhibiting Ras proteins, and their uses in the treatment of cancers.

  该披露涉及大环化合物，以及能够抑制Ras蛋白质的药物组合物和蛋白质复合物，以及它们在治疗癌症中的用途。
• [EN] MACROCYCLES AS CFTR MODULATORS<br/>[FR] MACROCYCLES EN TANT QUE MODULATEURS DE CFTR
  申请人：IDORSIA PHARMACEUTICALS LTD

  公开号：WO2022194399A1

  公开（公告）日：2022-09-22

  The present invention relates to macrocyclic compounds of Formula (I) wherein Ar1, Ar2, R1, R2, R3, R4, and X are as described in the description, their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of Formula (I), and especially to their use as modulators of CFTR.

  本发明涉及公式（I）的大环化合物，其中Ar1，Ar2，R1，R2，R3，R4和X如描述中所述，它们的制备方法，其药学上可接受的盐以及它们作为药物的用途，包括含有一个或多个公式（I）化合物的药物组合物，特别是它们作为CFTR调节剂的用途。